<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Varmeh S</submitter><funding>NIDDK NIH HHS</funding><funding>NCI NIH HHS</funding><pagination>152-62</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC4688239</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>159(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Investigating BRAF((V600E)) inhibitors (BRAFi) as a strategy to treat patients with aggressive thyroid tumors harboring the BRAF((V600E)) mutant currently is in progress, and drug resistance is expected to pose a challenge. MicroRNAs (miRNAs) are involved in development of resistance to a variety of drugs in different malignancies.&lt;h4>Methods&lt;/h4>miRNA expression profiles in the human anaplastic thyroid cancer cell line (8505c) were compared with its PLX4720-resistant counterpart (8505c-R) by the use of Illumina deep sequencing. We conducted a functional annotation and pathway analysis of the putative and experimentally validated target genes of the significantly altered miRNAs.&lt;h4>Results&lt;/h4>We identified 61 known and 2 novel miRNAs whose expression was altered greatly</pubmed_abstract><journal>Surgery</journal><pubmed_title>Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines.</pubmed_title><pmcid>PMC4688239</pmcid><funding_grant_id>P30 DK040561</funding_grant_id><funding_grant_id>R01 CA149738</funding_grant_id><funding_grant_id>1R01CA149738-01A1</funding_grant_id><pubmed_authors>Varmeh S</pubmed_authors><pubmed_authors>Sadreyev RI</pubmed_authors><pubmed_authors>Brauner E</pubmed_authors><pubmed_authors>Holm T</pubmed_authors><pubmed_authors>Vanden Borre P</pubmed_authors><pubmed_authors>Wang Y</pubmed_authors><pubmed_authors>Parangi S</pubmed_authors><pubmed_authors>Gunda V</pubmed_authors></additional><is_claimable>false</is_claimable><name>Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines.</name><description>&lt;h4>Background&lt;/h4>Investigating BRAF((V600E)) inhibitors (BRAFi) as a strategy to treat patients with aggressive thyroid tumors harboring the BRAF((V600E)) mutant currently is in progress, and drug resistance is expected to pose a challenge. MicroRNAs (miRNAs) are involved in development of resistance to a variety of drugs in different malignancies.&lt;h4>Methods&lt;/h4>miRNA expression profiles in the human anaplastic thyroid cancer cell line (8505c) were compared with its PLX4720-resistant counterpart (8505c-R) by the use of Illumina deep sequencing. We conducted a functional annotation and pathway analysis of the putative and experimentally validated target genes of the significantly altered miRNAs.&lt;h4>Results&lt;/h4>We identified 61 known and 2 novel miRNAs whose expression was altered greatly</description><dates><release>2016-01-01T00:00:00Z</release><publication>2016 Jan</publication><modification>2025-04-03T22:41:26.081Z</modification><creation>2019-03-27T02:05:40Z</creation></dates><accession>S-EPMC4688239</accession><cross_references><pubmed>26456124</pubmed><doi>10.1016/j.surg.2015.06.046</doi></cross_references></HashMap>